Intensified inflammatory reaction of actinic keratoses after single application of topical 5-fluorouracil in a patient treated with nilotinib for chronic myeloid leukemia

Dermatology

Volumn 219, Issue 4, 2009, Pages 341-343

  Schmid Wendtner, Monika Hildegard ^a   Wendtner, Clemens M ^b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

5 fluorouracil; Actinic keratosis; Chronic myeloid leukemia; Inflammation; Nilotinib

Indexed keywords

FLUOROURACIL; NILOTINIB;

ACTINIC KERATOSIS; AGED; ANAMNESIS; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER THERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL ASSESSMENT; CLINICAL FEATURE; FOLLOW UP; HUMAN; INFLAMMATION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, CUTANEOUS; AGED; ANTINEOPLASTIC AGENTS; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FLUOROURACIL; FOREHEAD; HUMANS; KERATOSIS, ACTINIC; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PYRIMIDINES; SCALP; TIME FACTORS; TREATMENT OUTCOME;

EID: 72449165347     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000221006     Document Type: Article

References (9)

1. Le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Kwong YL, Baccarani M, Hughes T, Martinelli G, Radich JP, Zheng M, Shou Y, Kantarjian H: Nilotinib (formerly AMN 107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinibresistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008; 15: 1834-1839.
2. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E: A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: A comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157(suppl 2):34-50.
3. Sander CA, Pfeiffer C, Kligman AM, Plewig G: Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin. J Am Acad Dermatol 1997; 36: 236-238.
4. M'barak LM, Mebazaa A, Euvrard S, Frances C, Thervet E, Morel P, Menasche S, Legendre C, Lebbe C: 5% topical imiquimod tolerance in transplant recipients. Dermatology 2007; 215: 130-133.
5. Higa GM, Kovach RF, Abraham J: Actinic keratosis and capecitabine therapy. J Oncol Pharm Pract 2005; 11: 151-153.
6. Ilvas EN, Grana G, Green JJ: Inflammatory actinic keratoses secondary to systemic chemotherapy. Cutis 2005; 75: 167-168.
7. Lacouture ME, Desai A, Soltani K, Petronic- Rosic V, Laumann AE, Ratain MJ, Stadler WM: Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol 2006; 31: 783-785.
8. Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, Diwan AH, Evans HL, Kurzrock R: Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol 2008; 144: 779-782.
9. Kawakami Y, Nakamura K, Nishibu A, Yanagihori H, Kimura H, Yamamoto T: Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment. Acta Derm Venereol 2008; 88: 185-186.